EU First-Half New Drug Approvals Rebound After Slump In 2023

 
• By Ian Schofield

The number of medicines containing a new active substance approved for pan-EU marketing in the first six months of 2024 rose to near-normal levels after an unusually sharp dip in the 2023 period. The approvals were again led by cancer drugs, with therapies for blood disorders a close second, while half of the approvals were treatments for rare diseases.

Onwards and Upwards, Path to Success, Man Walking on Arrow, Career Growth and Success
EU new drug approvals are on the rise again • Source: Shutterstock

More from Europe

More from Geography